Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited reports a transformative quarter, focusing on neurodegenerative diseases and strengthening its leadership. The company’s drug monepantel has been granted Orphan Drug Designation by the US FDA and has shown promising survival data in ALS treatment studies. With a successful capital raise of $17.8 million, PharmAust is well-positioned to advance its ALS therapy.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
